Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17853199 | 0.78 | GABRA1 (0.37) | GABRA1KMT2A | |
| SCHEMBL19730079 | 0.75 | KDM4C (0.41) | NPC1RAB9ASMN1; SMN2KAT2BBRD9 | |
| SCHEMBL14922175 | 0.75 | L3MBTL1 (0.38) | GABRA1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27478868 | 0.75 | GABRA1 (0.33) | GABRA1 | |
| SCHEMBL15998476 | 0.74 | ALDH1A1 (0.46) | NPC1RAB9ASMN1; SMN2KAT2BBRD9 | |
| SCHEMBL27783422 | 0.65 | POLB (0.51) | GABRA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16245836 | 0.64 | SLC9A1 (0.65) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23213625 | 0.62 | SMN1; SMN2 (0.42) | GABRA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16245853 | 0.62 | KMT2A (0.50) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8233543 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035774-B2 | Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds | MERCK SHARP & DOHME CORP. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | UROD, PEPD, CMPK1 | GABRA1 1252/4885NPC1 2836/4885RAB9A 1120/4885 |
| US-10035774-B2 | Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds | UROD, PEPD, CMPK1 | GABRA1 1252/4885NPC1 2836/4885RAB9A 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.